Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 108,269
  • Shares Outstanding, K 106,146
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,140 K
  • EBIT $ -25 M
  • EBITDA $ -25 M
  • 60-Month Beta 0.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1,358.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.06
  • Number of Estimates 1
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7890 +29.28%
on 02/11/26
1.1900 -14.29%
on 02/24/26
+0.0517 (+5.34%)
since 02/02/26
3-Month
0.7890 +29.28%
on 02/11/26
1.3000 -21.54%
on 01/22/26
+0.1400 (+15.91%)
since 12/02/25
52-Week
0.3258 +213.08%
on 06/06/25
1.5100 -32.45%
on 09/29/25
+0.3592 (+54.36%)
since 02/28/25

Most Recent Stories

More News
Stocks in play: Oncolytics Biotech Inc

Announced the initiation of a metastatic colorectal cancer Phase 2 study that will be referred to as ...

ONCY : 1.0200 (-9.73%)
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study

Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026 Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L...

ONCY : 1.0200 (-9.73%)
Stocks in play: Oncolytics Biotech Inc

Announced it has concluded enrollment in the GOBLET study, having generated the necessary clinical and ...

ONCY : 1.0200 (-9.73%)
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer

Company to wind down the GOBLET gastrointestinal study to focus on registration path in the U.S. With sufficient cash on hand to execute near-term milestones, the Company expects to avoid immediate...

ONCY : 1.0200 (-9.73%)
Stocks in play: Oncolytics Biotech Inc

Announced that the U.S. Food and Drug Administration has granted Fast Track Designation to pelareorep ...

ONCY : 1.0200 (-9.73%)
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer

Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat population Company to launch controlled study in second-line KRAS-mutant...

ONCY : 1.0200 (-9.73%)
Hard-to-Treat Cancers: How 2026’s Top Clinical Platforms Are Beating Industry Benchmarks

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The global oncology market is charging toward a massive $668 billion valuation by 2034[1], fueled by a...

ONCY : 1.0200 (-9.73%)
FHTX : 5.76 (+1.41%)
ORIC : 13.88 (+3.20%)
LLY : 1,017.97 (-3.23%)
GOVX : 1.5600 (-2.50%)
SLS : 5.05 (+2.43%)
Stocks in play: Oncolytics Biotech Inc

Today announced the voting results from its Special Meeting of Shareholders held on Thursday, January ...

ONCY : 1.0200 (-9.73%)
Oncolytics Biotech® Announces Results of Special Meeting of Shareholders

SAN DIEGO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“ Oncolytics ” or the “ Company ”), a clinical-stage immunotherapy company developing pelareorep, today...

ONCY : 1.0200 (-9.73%)

Business Summary

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated...

See More

Key Turning Points

3rd Resistance Point 1.2033
2nd Resistance Point 1.1667
1st Resistance Point 1.0933
Last Price 1.0200
1st Support Level 0.9833
2nd Support Level 0.9467
3rd Support Level 0.8733

See More

52-Week High 1.5100
Fibonacci 61.8% 1.0576
Last Price 1.0200
Fibonacci 50% 0.9179
Fibonacci 38.2% 0.7782
52-Week Low 0.3258

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar